Search results
Results from the WOW.Com Content Network
In this article, we discuss the 13 best genomics stocks to buy now. If you want to read about some more genomics stocks, go directly to 5 Best Genomics Stocks To Buy Now. Before talking about the ...
Investments include genomics stocks, energy and automation technologies, shared infrastructure and services as well as fintech innovators. ... Ease – Rather than needing to research and buy ...
Just two stocks with market caps larger than 10x Genomics' $2 billion have suffered steeper downticks. Revenue did decline in its latest quarter. Profitability it also several years away.
Its stock is a tracking stock of Applera, along with the tracking stock of Applera's larger Applied Biosystems Group business unit. Celera sequenced the human genome at a fraction of the cost of the publicly funded Human Genome Project (HGP), using about $300 million of private funding versus approximately $3 billion of taxpayer dollars.
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
In March 2013, Complete Genomics was acquired by BGI Group. [17] After the acquisition, Complete Genomics moved to San Jose, and in June 2018 became part of MGI. [18] [19] The acquisition was the one of the outcomes of $1.5 billion 'collaborative funds' i.e., '10 years loan' which was initially provided by China Development Bank to acquire all 128 of Illumina, Inc.'s newest and fastest next ...
For folks with a tolerance for risk, life sciences company Bionano Genomics (NASDAQ:BNGO) is definitely worth a look. It takes guts to invest in out-of-favor assets like BNGO stock, but the long ...